Welcome to the NNECOS Blog!

Please click on the orange RSS box below to subscribe to this blog.

  • 03 Feb 2017 6:32 PM | Lori Aubrey (Administrator)

    FDA granted accelerated approval to nivolumab (OPDIVO, Bristol-Myers Squibb Company) for treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with a platinum-containing chemotherapy.   February 2, 2017. More Information:


  • 25 Jan 2017 12:49 PM | Lori Aubrey (Administrator)

    NH HB 443, to prohibit prescription drug manufacturers from offering to pay or reimburse insurance copayment was discussed at a public hearing on January 4th. Learn more about the amendment introduced and issues surrounding this proposed legislation on our Legislative Advocacy page.

  • 20 Dec 2016 11:49 AM | Lori Aubrey (Administrator)

    DEA Eliminates Grace Period for Registration Renewal

    Through a notice on its website, the Drug Enforcement Administration (DEA) recently announced significant changes to its registration renewal process. Effective January 1, 2017, the DEA is eliminating the informal grace period which the agency has previously allowed for registrants to renew their registrations. Only one renewal notice will be sent to each registrant’s “mail to” address approximately 65 days prior to the expiration date; no other reminders to renew the DEA registration will be provided. The notice also advises that online capability to renew a DEA registration after the expiration date will no longer be available, and that failure to file a renewal application by midnight EST of the expiration date will result in the “retirement” of the registrant’s DEA number. The original DEA registration will not be reinstated. In addition, paper renewal applications will not be accepted the day after the expiration date. If DEA has not received the paper renewal application by the day of the expiration date, mailed in renewal applications will be returned and the registrant will have to apply for a new DEA registration.

    The American Medical Association (AMA) has strongly expressed its concerns to DEA about this change in policy and the problems it could create for both patients and their physicians throughletters sent Friday, December 9 to DEA Acting Administrator Charles Rosenberg and Louis Milione (Assistant Administrator for Diversion Control). These letters urged DEA to reverse the change to the renewal process.

  • 01 Dec 2016 7:57 PM | Lori Aubrey (Administrator)

    Applications for collaborative research funding accepted through 12/31/16.

  • 01 Dec 2016 10:34 AM | Lori Aubrey (Administrator)

    Check out the new Code Updates

  • 29 Nov 2016 1:18 AM | Lori Aubrey (Administrator)

    Check out the latest job posting for: Manager Clinical Trial Office at the University of Vermont Cancer Center

  • 22 Nov 2016 8:31 AM | Lori Aubrey (Administrator)

    FDA Approves daratumumab for multiple myeloma. Check out other recent approvals, label changes, and packaging updates at Drug Related Resources

  • 15 Nov 2016 9:31 AM | Lori Aubrey (Administrator)

    Our lunchtime webinar series returns on Wednesday, November 30th with a patient navigation webinar! Register today

  • 10 Nov 2016 3:33 PM | Lori Aubrey (Administrator)
  • 09 Nov 2016 11:57 AM | Lori Aubrey (Administrator)

Northern New England Clinical Oncology Society
P.O. Box 643
Sandown, NH 03873-0643
Telephone (603) 887-1948

This website brought to you by:

Powered by Wild Apricot Membership Software